Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan plus carboplatin versus standard platinum-based doublets in platinum-sensitive recurrent ovarian, peritoneal, or fallopian tube cancer
2006-004628-34Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of topotecan, carboplatin, paclitaxel, gemcitabine and doxorubicin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: 12-month progression-free survival rate. Started Dec 2006; status: completed.
02
Drugs
topotecancarboplatinpaclitaxelgemcitabinedoxorubicin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2006-004628-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004628-34.